Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia
Mark Biagi, D. Lamm, K. Meyer, A. Vialichka, M. Jurkovic, Shitalben Patel, Rodrigo E. Mendes, Zackery P. Bulman, Eric Wenzler
Abstract
The intrinsic L1 metallo- and L2 serine-β-lactamases in Stenotrophomonas maltophilia make it naturally multidrug resistant and difficult to treat. There is a need to identify novel treatment strategies for this pathogen, especially against isolates resistant to first-line agents. Aztreonam in combination with avibactam has demonstrated potential, although data on other aztreonam–β-lactamase inhibitor (BLI) combinations are lacking. Additionally, molecular mechanisms for reduced susceptibility to these combinations have not been explored.
Topics & Concepts
Stenotrophomonas maltophiliaCeftazidime/avibactamMedicineAztreonamMultiple drug resistanceGram-negative bacterial infectionsMicrobiologyAntibioticsBiologyPseudomonas aeruginosaAntibiotic resistanceBacteriaImipenemCeftazidimeGeneticsInfections and bacterial resistanceHemostasis and retained surgical itemsBacterial biofilms and quorum sensing